Vasoactive intestinal peptide inhibits cytokine production in T lymphocytes through cAMP-dependent and cAMP-independent mechanisms

Regulatory Peptides

Volumn 84, Issue 1-3, 1999, Pages 55-67

  Wang, Hong Ying ^a   Jiang, Xiaoming ^a   Gozes, Illana ^b   Fridkin, Mati ^c   Brenneman, Douglas E ^d   Ganea, Doina ^a  

^a RUTGERS UNIVERSITY   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d Lab Devmtl Neurbio   (United States)

Author keywords

antagonists; IL 10; IL 2; PACAP; Transduction pathways.; VIP agonists

Indexed keywords

CYCLIC AMP; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERLEUKIN 10; INTERLEUKIN 2; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOPRESSIN ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL SURVIVAL; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; CELLS, CULTURED; CONCANAVALIN A; CYCLIC AMP; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0032830273     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(99)00068-3     Document Type: Article

References (42)

1. Gozes I., Brenneman D.E. Neuropeptides as growth and differentiation factors in general and VIP in particular. Mol. Neurosci. 4:1993;1-9.
2. Gressens P., Hill J.M., Gozes I., Fridkin M. Brenneman, D.E. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature. 362:1993;155-158.
3. Brenneman D.E., Phillips T.M., Festoff B.W., Gozes I. Identity of neurotrophic molecules released from astroglia by vasoactive intestinal peptide. Ann NY Acad. Sci. 814:1997;167-173.
4. Ganea D. Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Adv. Neuroimmunol. 6:1996;61-74.
5. Sun L., Ganea D. VIP inhibits IL-2 and IL-4 production through different mechanisms in T cells activated via the TCR/CD3 complex. J. Neuroimmunol. 48:1993;59-70.
6. Tang H., Sun L., Xin Z., Ganea D. Downregulation of cytokine expression in murine lymphocytes by PACAP and VIP. Ann. NY Acad. Sci. 805:1996;768-778.
7. Wang H-Y, Xin Z., Tang H., Ganea D. Vasoactive intestinal peptide inhibits IL-4 production in murine T cells by a post-transcriptional mechanism. J. Immunol. 156:1996;3243-3253.
8. Martinez C., Delgado M., Gomariz R.P., Ganea D. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP38) inhibit IL10 production in murine T lymphocytes. J. Immunol. 156:1996;4128-4136.
9. Rawlings S.R., Hezareh M. Pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. Endocrine Reviews. 17:1996;4-29.
10. Gozes I., McCune S.K., Jacobson L., Warren D., Moody T.W., Fridkin M., Brenneman D.E. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J. Pharmacol. Exp. Therapeut. 257:1991;959-966.
11. Gozes Y., Brenneman D.E., Fridkin M., Asofsky R., Gozes I. A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes. Brain Res. 540:1991;319-321.
12. Usdin T.R., Bonner T.I., Mrzey E. Two receptors for vasoactive intestinal peptide with similar specificity and complementary distributions. Endocrinology. 135:1994;2662-2680.
13. Gozes I., Lilling G., Glazer R., Ticher A., Ashkenazi I.E., Davidson A., Rubinraut S., Fridkin M., Brenneman D.E. Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J. Pharmacol. Exp. Therapeut. 273:1995;161-166.
14. Gozes I., Lilling G., Davidson A., Bardea A., Reshef A., Glazer R., Zamostiano R., Ashur-Fabian O., Ticher A., Ashkenazi I.E., Moody T.W., Rubinraut S., Fridkin M., Brenneman D.E. Development of V.I.P. agonists and antagonists with tissue and receptor specificity: effects on behavioral maturation, sexual function, and the biological clock. Ann. NY Acad. Sci. 805:1996;59-171.
15. Gomariz R.P., Garrido E., Leceta J., Martinez C., Abalo R., Delgado M. Gene expression of VIP receptor in rat lymphocytes. Biochem. Biophys. Res. Commun. 203:1994;599-1604.
16. Delgado M., Martinez C., Johnson M., Gomariz R.P., Ganea D. Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) in murine lymphocytes. J. Neuroimmunol. 68:1996;27-38.
17. Johnson M., McCormack R., Delgado M., Martinez C., Ganea D. Murine T lymphocytes express vasoactive intestinal peptide receptor 1 (VIP-R1) mRNA. J. Neuroimmunol. 68:1996;109-119.
18. Jiang X., Wang H-Y, Yu J., Ganea D. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes. Ann. NY Acad. Sci. 865:1998;397-407.
19. Novak T.J., Rothenberg E.V. cAMP inhibits induction of IL-2 but not IL-4 in T cells. Proc. Natl. Acad. Sci. USA. 87:1990;9353-9358.
20. Anastassiou E.D., Paliogianni F., Balow J.P., Yamada H., Boumpas D.T. PGE2 and other cAMP elevating agents modulate IL-2 and IL-2Rα gene expression at multiple levels. J. Immunol. 148:1992;2845-2852.
21. Katamura K., Shintaku N., Yamauchi Y., Fukui T., Ohshima Y., Mayumi M., Furusho K. Prostaglandin E2 at priming of naive CD4+ T cells inhibits acquisition of ability to produce IFNγ and IL-2, but not IL-4 and IL-5. J. Immunol. 155:1995;4604-4612.
22. Tang H., Welton A., Ganea D. Neuropeptide regulation of cytokine expression. Effects of VIP and Ro 25-1553. J. Interferon Cytokine Res. 15:1995;993-1003.
23. 2 receptor subclass. Peptides. 18:1997;403-408.
24. Xia M., Sreedharan S.P., Bolin D.R., Gaufo G.O., Goetzl E.J. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J. Pharmacol. Exp. Ther. 281:1997;629-633.
25. Schaad N.C., Vanecek J., Rodriguez I.R., Klein D.C., Holtzclaw L., Russell J.T. Vasoactive intestinal peptide elevates pinealocyte intracellular calcium concentrations by enhancing influx: evidence for involvement of a cGMP-dependent mechanism. Molec. Pharmacol. 47:1995;923-933.
26. Murphy K.S., Jin J.G., Grider J.R., Makhlouf G.M. Characterization of PACAP receptors and signaling pathways in rabbit gastric muscle cells. Am. J. Physiol. 272:1997;G1391-G1399.
27. Bauer H., Jung T., Tsikas D., Stichtenoth D.O., Frolich J.C., Neumann C. Nitric oxide inhibits the secretion of T helper 1 and T helper 2 associated cytokines in activated human T cells. Immunology. 90:1997;205-211.
28. Xin Z., Jiang X., Wang H-Y, Denny T.N., Dittel B.N., Ganea D. Effect of vasoactive intestinal peptide (VIP) on cytokine production and expression of VIP receptors in thymocyte subsets. Regul. Pept. 72:1997;41-54.
29. Boudard F., Bastide M. Inhibition of mouse T cell proliferation by CGRP and VIP. J. Neurosci. Res. 29:1991;29-41.
30. Inagaki N., Yoshida H., Mizuta M., Mizuno N., Fujii Y., Gonoi T., Miyazaki J., Susumu S. Cloning and functional characterization of a third PACAP receptor subtype expressed in insulin-secreting cells. Proc. Natl. Acad. Sci. USA. 91:1994;2679-2683.
31. Sreedharan S.P., Patel D.R., Huang J.X., Goetzl E.J. Cloning and functional expression of a human VIP receptor. Biochem. Biophys. Res. Commun. 193:1993;546-553.
32. Lutz E.M., Sheward W.J., West K.M., Morrow J.A., Fink G., Harmar A.J. The VIP2 receptor: molecular characterization of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett. 334:1993;3-8.
33. Ashur-Fabian O., Giladi E., Brenneman D.E., Gozes I. Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides. J. Mol. Neurosci. 9:1997;211-222.
34. Chen D., Rothenberg E.V. IL-2 transcription factors as molecular targets of cAMP inhibition: delayed inhibition kinetics and combinatorial transcription roles. J. Exp. Med. 179:1994;931-942.
35. Tsuruta L., Lee H-J, Masuda E.S., Koyano-Nakagawa N., Arai N., Arai K., Yokota T. cAMP inhibits expression of the IL-2 gene through the NFAT site, and transfection of NFAT cDNAs abrogates the sensitivity of EL-4 cells to cAMP. J. Immunol. 154:1995;5255-5264.
36. Ho H-Y, Lee H-H, Lai M-Z. Overexpression of mitogen-activated protein kinase kinase reversed cAMP inhibition of NFkB in T cells. Eur. J. Immunol. 27:1997;222-226.
37. Hsueh Y-P, Lai M-Z. C-jun N-terminal kinase but not mitogen-activated protein kinase is sensitive to cAMP inhibition in T lymphocytes. J. Biol. Chem. 270:1995;18094-18098.
38. Tamir A., Granot Y., Isakov N. Inhibition of T lymphocyte activation by cAMP is associated with downregulation of two parallel mitogen-activated protein kinase pathways, the extraacellular signal-related kinase and c-Jun N-terminal kinase. J. Immunol. 157:1996;1514-1522.
39. Bodor J., Spetz A-L, Strominger J.L., Habener J.F. cAMP inducibility of transcriptional repressor ICER in developing and mature human T lymphocytes. Proc. Natl. Acad. Sci. USA. 93:1998;3536-3541.
40. Zorn N., Russell D.H. Vasoactive intestinal peptide activation of nuclear protein kinase C in purified nuclei of rat splenocytes. Biochem. Pharmacol. 40:1990;2689-2694.
41. Fatatis A., Holtzclaw L.A., Avidor R., Brenneman D.E., Russell J.T. Vasoactive intestinal peptide increases intracellular calcium in astroglia: synergism with alpha-adrenergic receptors. Proc. Natl. Acad. Sci. USA. 91:1994;2036-2040.
42. Stallwood D., Brugger C.H., Baggenstoss B.A., Stemmer P.M., Shiraga H., Landers D.F., Paul S. Identity of a membrane-bound vasoactive intestinal peptide-binding protein with calmodulin. J. Biol. Chem. 267:1992;19617-19621.